Financial Reports

RaySearch Laboratories AB (publ) Year-end Report 2009

JANUARY 1 – DECEMBER 31, 2009 • Net sales for the period amounted to SEK 83.7 M (62.7) • Profit after tax totaled SEK 30.1 M (18.2) and earnings per share amounted to SEK 0.88 (0.53) • Operating profit totaled SEK 40.9 M (21.1) • Cash flow amounted to SEK 9.4 M (neg: 8.5) • A breakthrough order for a proton treatment planning system was secured in June • The new VMAT product from the collaboration with Philips began generating revenues in November • The collaboration agreement with Siemens, which was signed in May, has been expanded and was accelerated in November • Two new products from the collaboration with Nucletron began generating revenues in December • The collaboration with Varian, which encompassed three new products, began generating revenues in December • The first order was received for the new product from the collaboration with TomoTherapy • The Board of Directors proposes a dividend of SEK 0.50 (0) per share “The year 2009 was extremely successful for RaySearch, with several exciting product launches. The new products began generating substantial revenues toward the end of the year, leading to a revenue increase of a full 71 percent in the fourth quarter,” says Johan Löf, President of RaySearch. “I can therefore state that we have entered a new phase of growth and are very well prepared for the future,” concludes Johan Löf.